Top

Published in:

01-06-2019 | Empagliflozin | Research Letter

Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus

Authors: Chantal Kopecky, Yuliya Lytvyn, Oliver Domenig, Marlies Antlanger, Johannes J. Kovarik, Christopher C. Kaltenecker, Marko Poglitsch, Bruce A. Perkins, Kerry-Anne Rye, David Z. I. Cherney, Marcus D. Säemann

Published in: Diabetologia | Issue 6/2019

Excerpt

To the Editor: Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are a highly promising class of glucose-lowering therapies and have been found to reduce cardiovascular and kidney disease risk in patients with type 2 diabetes [1‐3]. The mechanisms underlying these cardio- and renoprotective effects of SGLT-2 inhibition are, however, incompletely understood and it is not known if these beneficial effects are also evident in people with type 1 diabetes. …

Available only for authorised users

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720 CrossRefPubMed

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925 CrossRefPubMed

Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920 CrossRefPubMed

Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124(6):2333–2340. https://doi.org/10.1172/JCI72271 CrossRefPubMedPubMedCentral

Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587–597. https://doi.org/10.1161/CIRCULATIONAHA.113.005081 CrossRefPubMed

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752–772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887 CrossRefPubMed

Roksnoer LC, van Veghel R, de Vries R et al (2015) Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats. Kidney Int 88(1):109–120. https://doi.org/10.1038/ki.2015.107 CrossRefPubMed

Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal ras activity in people with type 1 diabetes. Kidney Int 86(5):1057–1058. https://doi.org/10.1038/ki.2014.246 CrossRefPubMed

Klein WS, Merz CN, Jenkins MR (2014) Guidelines for managing high blood pressure. JAMA 312(3):294–295. https://doi.org/10.1001/jama.2014.6593 CrossRefPubMed

Title: Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus
Authors: Chantal Kopecky
Yuliya Lytvyn
Oliver Domenig
Marlies Antlanger
Johannes J. Kovarik
Christopher C. Kaltenecker
Marko Poglitsch
Bruce A. Perkins
Kerry-Anne Rye
David Z. I. Cherney
Marcus D. Säemann
Publication date: 01-06-2019
Publisher: Springer Berlin Heidelberg
Keywords: Empagliflozin
Diabetes
Type 1 Diabetes
Published in: Diabetologia / Issue 6/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-019-4871-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Molecular regulation of the renin–angiotensin system by sodium–glucose cotransporter 2 inhibition in type 1 diabetes mellitus

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2019

Large enteroviral vaccination studies to prevent type 1 diabetes should be well founded and rely on scientific evidence. Reply to Skog O, Klingel K, Roivainen M et al [letter]

Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status

Pregnancy in human IAPP transgenic mice recapitulates beta cell stress in type 2 diabetes

No direct effect of SGLT2 activity on glucagon secretion

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page